Quantcast
Free Trial!
Today’s Best Stocks To Trade!  Click Here


 

Church & Dwight Completes Purchase of Orajel and Other OTC Brands

Mon. July 07, 2008; Posted: 02:39 PM
Stocks RSS
7 Stocks You Need To Know For Tomorrow -- Free Newsletter
PRINCETON, N.J., Jul 07, 2008 (BUSINESS WIRE) -- CHD | Quote | Chart | News | PowerRating -- Church & Dwight Co., Inc. (NYSE:CHD), makers of Arm & Hammer(R) products, today announced that it has completed its previously announced acquisition of the Del OTC pharmaceutical business from Coty Inc.

The transaction was completed substantially under the original terms announced on April 1, 2008, which called for Church & Dwight to pay $380 million in cash at closing.

The purchase price was financed with a $250 million addition to its bank credit facility and available cash.

"The Orajel brand will be a great addition to the Church & Dwight family," said James R. Craigie, Chairman and Chief Executive Officer. "We are excited to expand our personal care portfolio and strengthen our presence in the strategic oral care category."

As previously announced, the acquisition is expected to have a neutral impact on 2008 earnings per share due primarily to one-time integration costs and the step-up of inventory. "We expect it to be accretive in 2009 and contribute meaningfully to earnings and free cash flow," Mr. Craigie concluded.

Church & Dwight Co., Inc. manufactures and markets a wide range of personal care, household and specialty products under the Arm & Hammer brand name and other well-known trademarks.

This release contains forward-looking statements relating, among others, to the acquisition of the assets of Del Pharmaceuticals with respect to, the effect of the acquisition on earnings per share and free cash flow. These statements represent the intentions, plans, expectations and beliefs of Church & Dwight, and are subject to risks, uncertainties and other factors, many of which are outside the Company's control and could cause actual results to differ materially from such forward-looking statements, including but not limited to the risks associated with the successful integration of the Del Pharmaceuticals acquisition. The uncertainties include assumptions as to market growth and consumer demand (including the effect of political and economic events on consumer demand), raw material and energy prices, the financial condition of major customers, and marketing spending. Other factors, which could materially affect the results, include the outcome of contingencies, including litigation, pending regulatory proceedings and environmental remediation. For a description of additional cautionary statements, see Church & Dwight's quarterly and annual reports filed with the SEC.

SOURCE: Church & Dwight Co., Inc.

Church & Dwight Co., Inc. Matthew T. Farrell Chief Financial Officer 609-683-5900

For full details on Church & Dwight Co Inc (CHD) click here. Church & Dwight Co Inc (CHD) has Short Term PowerRatings of 5. Details on Church & Dwight Co Inc (CHD) Short Term PowerRatings is available at This Link.
Morning Coffee with TradingMarkets -- Free Newsletter

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Stocks RSS





Most Popular News
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2008 The Connors Group, Inc.